Medical treatment of urinary incontinence in the bitch

Medicamenteuze behandeling van urinaire incontinentie bij de teef

J. Timmermans, B. Van Goethem, H. de Rooster, D. Paepe

Small Animal Department, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium

bart.vangoethem@ugent.be

ABSTRACT

Urinary incontinence, an uncontrolled urine leakage during the storage phase of micturition, is a common condition in female dogs. In intact bitches, the reported prevalence is only 0.2-0.3%, but in spayed bitches it varies between 3.1-20.1%. Most commonly, dogs with acquired urinary incontinence suffer from urethral sphincter mechanism incompetence. This condition seems to be multifactorial, and although the exact pathophysiology remains unclear, potential risk factors include gender, gonadectomy, breed, body weight, urethral length and bladder neck position. In daily practice, the diagnosis of urethral sphincter mechanism incompetence is usually made after eliminating other potential causes of urinary incontinence. Incontinent bitches are primarily treated with medications, such as alpha-adrenergic drugs, e.g. phenylpropanolamine and oestrogens. Surgery is recommended when patients become refractory to medical treatment.

ANATOMY

The lower urinary tract consists of the bladder, comprised of an apex, body and bladder neck, and the urethra, containing the external urethral sphinc-
The external urethral sphincter could also be described as part of the sphincter mechanism and not as a separate structure. Micturition is coordinated through sympathetic, parasympathetic and somatic innervation, combined with actions regulated from central control centers (DiBartola and Westropp, 2014) (Figure 1). The sympathetic hypogastric nerve, originating from spinal segment L1-L4, is mainly important during the storage phase because norepinephrine release during nerve stimulation results in detrusor relaxation, filling of the urinary bladder and prevention of subsequent urinary leakage (Fischer and Lane, 2011; DiBartola and Westropp, 2014; Byron, 2015). This is accomplished through activation of beta-receptors in the bladder and alpha-1-adrenergic receptors in the smooth muscle within the urethral sphincter mechanism (DiBartola and Westropp, 2014). The pelvic nerve, which originates from spinal segment S1-S3, supplies parasympathetic innervation (Fischer and Lane, 2011). It ensures excitatory input to the bladder (bladder contraction) and inhibitory input to the urethra (urethral relaxation), resulting in urination (DiBartola and Westropp, 2014). Lastly, the pudendal nerve also originates from spinal segment S1-S3, supplies somatic innervation and stimulates the external urethral sphincter (Fischer and Lane, 2011; DiBartola and Westropp, 2014).

**URETHRAL SPHINCTER MECHANISM INCOMPETENCE**

Dogs with acquired UI most commonly suffer from urethral sphincter mechanism incompetence (USMI) (Byron et al., 2017). The pathophysiology of USMI remains incompletely elucidated. Most likely, this condition is multifactorial, resulting from hormonal, as well as structural and functional changes (Applegate et al., 2018). Several risk factors have been described for the development of USMI.

**Gender**

USMI can develop in both male and female dogs, but the condition is rare in males with a reported risk of up to 1% (Holt, 1990; Reichler and Hubler, 1994).

<table>
<thead>
<tr>
<th>Urinary incontinence</th>
<th>Neurogenic</th>
<th>Non-neurogenic</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Lower motor neuron disorders</td>
<td>• Urethral sphincter mechanism incompetence (USMI)</td>
<td></td>
</tr>
<tr>
<td>• Upper motor neuron disorders</td>
<td>• Congenital disorders</td>
<td></td>
</tr>
<tr>
<td>• Detrusor urethral dyssynergia</td>
<td>• Detrusor hyperreflexia</td>
<td></td>
</tr>
<tr>
<td>• Dysautonomia</td>
<td>• Anatomical or functional urethral obstruction leading to secondary bladder atony</td>
<td></td>
</tr>
<tr>
<td>• Primary bladder atony</td>
<td>• Bladder atony due to muscle weakness or medications</td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Main differential diagnoses of urinary incontinence. Adapted from: Fischer and Lane (2017).

Figure 1. Simplified representation of the innervation of the lower urinary tract. Adapted from: DiBartola and Westropp (2014).
2014). Extensive studies have been conducted in bitches to support the prevalence, which is not the case in males (Aaron et al., 1996; Forsee et al., 2013).

**Gonadectomy**

Spaying in dogs increases the risk of USMI (Holt and Thrushfield, 1993; Thrushfield et al., 1998; Reichler and Hubler, 2014). According to Holt (1985), approximately 90% of dogs with USMI have a history of prior gonadectomy. In about 75% of the bitches, the onset of UI occurs within three years after gonadectomy, but it is not uncommon that clinical signs occur directly after the surgery or as late as ten years after (Arnold et al., 1989; Reichler and Hubler, 2014).

So far, no consensus has been reached about the link between the age of the dog at spaying and the concurrent risk of USMI (Arnold et al., 1989; Arnold, 1997; Thrushfield et al., 1998; Stöcklin-Gautschi et al., 2001; de Bleser et al., 2011; Beauvais et al., 2012; Forsee et al., 2013; Reichler and Hubler, 2014). In earlier studies, an increased risk of developing incontinence has been mentioned when spaying was performed before three months of age (Thrushfield et al., 1998; Stöcklin-Gautschi et al., 2001), or when dogs have had their first oestrus (Arnold et al., 1989). On the other hand, in more recent publications, no evidence to support a relationship between age at which gonadectomy is performed and the development of USMI in bitches has been found (de Bleser et al., 2011; Beauvais et al., 2012; Forsee et al., 2013). The suggestion has been made that the severity of UI might be different depending on the age the animal was spayed (Reichler and Hubler, 2014). In a study by Arnold (1997), it was shown that gonadectomy before puberty resulted in UI after an increased abdominal pressure, as expected, but also during walks or when the animal was awake. Dogs neutered after puberty are mainly dribbling when recumbent with less intensity (Stöcklin-Gautschi et al., 2001).

Recently, Byron et al. (2017) described a relationship between gonadectomy and body weight, which will be discussed below.

The extent of surgery, ovariectomy versus ovariohysterectomy, does not result in different continence rates (Van Goethem et al., 2006). Likewise, the incidence of USMI is not different in dogs with elective versus emergency procedure (Forsee et al., 2013).

**Breed and body weight**

Urinary incontinence is more common in medium to large-breed dogs (de Bleser et al., 2011). Previous studies have demonstrated that dogs weighing more than 10 kg have a 3.7-times higher risk of developing USMI than smaller dogs (de Bleser et al., 2011), and dogs weighing more than 15 kg have a 7.2-times higher risk (Forsee et al., 2013). Additionally, Byron et al. (2017) found a relationship between age at the time of ovariohysterectomy and body weight in developing USMI. According to this study, the risk of developing USMI for dogs with an expected adult weight of more than 25 kg decreases for every month gonadectomy is postponed during their first year. In the same study, dogs weighing less than 15 kg were reported not to be susceptible to this risk, making it reasonable to spay these dogs prior to the first heat to reduce the risk of unwanted pregnancy or developing mammary neoplasia and pyometra (Byron et al., 2017). Some breeds are clearly overrepresented in the literature and have an increased risk of USMI, such as Doberman pinscher, Old English sheepdog, Springer spaniel, boxer, rottweiler, Weimaraner, Giant schnauzer and Irish setter (White, 2001; Reichler and Hubler, 2014). Based on an investigation in 928 entire or neutered male and female Dobermans, a prevalence of 15.8% was found (Mandigers et al., 2006). Nevertheless, developing USMI is not restricted to these breeds; all breeds can be affected.

**Urethral length and bladder neck position**

Holt (1985c) documented that incontinent bitches are more likely to present with intrapelvic bladder neck than continent bitches that usually have intrabdominal bladder neck (Holt, 1985b). Radiographically, spayed bitches also tend to have a shorter urethra than intact bitches, although it is unknown how decisive these radiographic findings are in the occurrence of UI (Holt, 1985c; Wang et al., 2006).

**DIAGNOSIS**

Diagnosing USMI may be challenging and typically relies on elimination of other potential causes of UI (Applegate et al., 2018) (Table 1). Congenital conditions, e.g. ectopic ureter and patent urachus, must be evaluated in case an animal is incontinent since birth or at least before spaying (Byron, 2015). Affected dogs may present with either intermittent or continuous UI (Holt, 1985c), and observing micturation increases the chance of correct diagnosis (Byron, 2015). It is important to monitor for conscious or unconscious urination, stranguria and to palpate the bladder afterwards for residual volume (Byron, 2015). Findings on general physical examination are unfortunately not specific for the presence of USMI (Applegate et al., 2018). Neurological examination is indicated with particular interest for the urogenital system to evaluate the perineal reflex (pudendal nerve), as well as a vaginal and rectal examination to diagnose anatomical abnormalities (Labato, 2018).

Additional diagnostic procedures are necessary to diagnose USMI (Applegate et al., 2018). The ideal diagnostic work-up to support the presumptive diagnosis of USMI includes a complete blood count, biochemistry panel, urinalysis (including urine specific
MEDICAL TREATMENT

Medical management is always the first treatment option because it is not invasive and successful in up to 97% of cases (Applegate et al., 2018). Alpha-adrenergic drugs are the preferred initial treatment in dogs with USMI (Richter and Ling, 1985; Applegate et al., 2018). It is important to know the potential side effects and contraindications of the medications described below to decide on the best choice of drugs and alter treatment accordingly.

Alpha-adrenergic drugs

Phenylpropanolamine, a sympathomimetic alpha-adrenergic drug, increases urethral sphincter tone by toning muscles in both the bladder neck and urethra (Richter and Ling, 1985; Scott et al., 2002; Applegate et al., 2018). The reported efficacy of this drug varies between 86-97% (Scott et al., 2002; Claeyss et al., 2011). One mg/kg body weight is administered two to three times a day (Scott et al., 2002), or alternatively 1.5 mg/kg body weight can be administered once daily (Claeyss et al., 2011). Improvement should be noticed within three to four weeks after starting treatment (Applegate et al., 2018). Side effects of phenylpropanolamine include anxiety, excitement and aggression, which may result in an increased sympathetic tone (Burgherr et al., 2007). Other alpha-adrenergic drugs, such as ephedrine or pseudoephedrine, illustrate more adverse effects, e.g. panting, hyporexia and lethargy, result in lower urethral closure pressure and have a lower efficacy of 25-75% only (Byron et al., 2007; Applegate et al., 2018). Phenylpropanolamine or other alpha-adrenergic drugs are contraindicated when hypertension could have disastrous consequences, e.g. in heart and kidney disease or glaucoma (Burgherr et al., 2007).

The effect of alpha-adrenergic drugs decreases over time (Richter and Ling, 1985; White and Pomeroy, 1989; Reichler and Hubler, 2014). Unfortunately, there is no cut-off period available from previously published studies as to when to expect decreased effect of medications or refractory incontinence.

Oestrogens

Estriol, a short-acting oestrogen, increases urethral closure pressure by stimulating urethral mucosal tissue (Mandigers and Nell, 2001). The reported efficacy is 65-83% (Arnold, 1997; Mandigers and Nell, 2001). A dose of 2 mg, irrespective of the dog’s bodyweight, is administered orally once daily for the first seven to fourteen days (Byron, 2018). Clinical improvement may be expected within this time frame (Mandigers and Nell, 2001). The recommended dose is reduced after improvement by 0.5 mg per week until the minimum effective dose is reached, which can be continued every other day (Mandigers and Nell, 2001; Fischer and Lane, 2017). If no response to treatment is achieved after the first two weeks, it may be beneficial to continue dosing 2 mg/dog until clinical improvement is appreciated (Mandigers and Nell, 2001). Potential adverse effects include vulvar hyperplasia, vaginal discharge, attractiveness to males and pyometra in entire and ovariectomized bitches (Byron et al., 2007; Schotanus et al., 2008; Applegate et al., 2018). Alternatively, diethylstilbestrol can be administered, which is a long-acting oestrogen. However, this could induce more adverse effects than estriol, such as myelosuppression (Hoeijmakers et al., 2003; Sontas et al., 2009).

Multidrug therapy

When monotherapy does not provide satisfactory results, multidrug therapy may be initiated (Aaron et al., 1996; Reichler et al., 2003). For example, combining alpha-adrenergic drugs with oestrogens would theoretically result in a synergistic effect because of their different mechanism of action (Aaron et al., 1996; Applegate et al., 2018). No recommendations have been published regarding altered dosing schedules or the consequences of this drug combination protocol on potential side effects. Hamaide et al. (2006) used the doses described above for phenylpropanolamine and estriol to investigate urodynamic and morphologic changes, but multidrug therapy did not appear beneficial compared to monotherapy.

Reichler et al. (2003) described a combination therapy of gonadotropin-releasing hormone (GnRH) analogues and phenylpropanolamine 1.5 mg/kg three times a day in dogs. Leuprolide, deslorelin and buserelin, examples of GnRH analogues, are injected subcutaneously and result in a suppression of follicle stimulating hormone and luteinizing hormone. The doses used include 11.25 mg, 5-10 mg, and 6.3 mg, respectively. These formulations are effective between one to six months (Reichler et al., 2003). Although the consequences to the urethral sphincter tone are incompletely elucidated, these GnRH analogues seem

gravity and urine culture), abdominal radiographs and abdominal ultrasound. Although most of these diagnostics are within normal limits when USMI is present in a dog, these tests should be performed to rule out concurrent diseases (Applegate et al., 2018). Performing abdominal radiographs and/or ultrasound allows excluding the presence of urinary calculi and neoplasia including possible metastatic disease. Urodynamic studies should be performed to make the definitive diagnosis of USMI (Applegate et al., 2018). When a minimum database is obtained but the specialized equipment for urodynamic studies is not available, it is acceptable to start empirical treatment and confirm the diagnosis of USMI as a result of treatment success (Applegate et al., 2018). However, diagnostics should be repeated in case of a recurrence of UI (Reichler and Hubler, 2014).
to have temporary positive effects in almost 50% of dogs with USMI (Reichler et al., 2003, 2006). Long-term results of GnRH solo treatment are disappointing, with only a few dogs still continent after a mean of 247 days even after repeated injections. So far, no side effects of this treatment have been mentioned (Reichler et al., 2003).

Refractory patients

Refractory patients are dogs that do not respond or tolerate medical treatment, or initially respond to medications and ultimately show clinical symptoms suggestive for USMI. It has been reported that up to 56% of dogs develop refractory incontinence (Currao et al., 2013). Treatment options for these patients include surgical treatment, such as urethral bulking, colposuspension, urethropexy and an artificial urethral sphincter (Applegate et al., 2018).

CONCLUSION

Approximately 3-5% of spayed bitches are affected with UI. USMI is the most common cause of acquired UI in spayed bitches and the frequency is influenced by gender, breed, body weight, gonadectomy, urethral length and bladder neck position. Diagnosing USMI is usually based on excluding other causes of incontinence and can be confirmed after performing urodynamic studies. USMI is primarily treated with medications, such as phenylpropanolamine and estradiol, of which the former is the treatment of choice. Additional scientific research and a longer follow-up period are required to further investigate what causes refractory incontinence, the benefits of multidrug therapy including the dosing schedules required in practice, and when refractory incontinence is likely to occur. Surgery is recommended when bitches become refractory to medical treatment of UI.

REFERENCES


the urogenital tract after administration of oestriol alone and in combination with phenylpropanolamine in sexually intact and spayed female dogs. *American Journal of Veterinary Research* 67, 901–908.


